RE: Importance Of AI For Kidney Patients25 Sep 2025 11:46
Good post from Kubera369 on Advfn -
Absolutely! they cannot even estimate what impact putting the test onto the EHR for physicians to prescribe for a patient because the numbers just unthinkable if this becomes the defactor test for Diabetes Tyoe 2 patients. Of the 22,000 physicians this test will be available to if it is subscribes to just 5% of the patients of which there are 4.4m to chosse from that would generate a demain for hundreds of thousands of tests at the Renalytix lab which means they would have already had to partner with another lab giant to service the demand or decentralise into the hospital network and suddenly within months this company is a company of $200m + which would bounce this share into the £1's
And lets not forget this is not a product that needs manufacturing facilities, this is a line added to a test catalogue on the EHR portal that the physician clicks on, submits the request, the patient has a blood test, its sent to Renalytix and the result are electronically sent back to the EHR patient records on the portal....
As simple as ordering an UBER or the new burger on the burger chain app or kiosk in store...
That's why this is a REAL opportunity to invest now at pence and reap the pounds in the next few months as the Tempus partnership pays off..
I've done my required DD and am already seeing this share price in the £££'s
I am getting my family and friends to buy in this as this is going to be massive!!!
Sign In
Follow the stocks
